Basics |
NovoCure Limited Ordinary Shares
NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.
|
IPO Date: |
September 28, 2015 |
Sector: |
Healthcare |
Industry: |
Medical Instruments and Supplies |
Market Cap: |
$1.87B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.33 | 2.70%
|
Avg Daily Range (30 D): |
$0.40 | 2.31%
|
Avg Daily Range (90 D): |
$0.42 | 2.41%
|
Institutional Daily Volume |
Avg Daily Volume: |
.77M |
Avg Daily Volume (30 D): |
1M |
Avg Daily Volume (90 D): |
.86M |
Trade Size |
Avg Trade Size (Sh.): |
72 |
Avg Trade Size (Sh.) (30 D): |
61 |
Avg Trade Size (Sh.) (90 D): |
59 |
Institutional Trades |
Total Inst.Trades: |
4,955 |
Avg Inst. Trade: |
$3.62M |
Avg Inst. Trade (30 D): |
$2.66M |
Avg Inst. Trade (90 D): |
$2.66M |
Avg Inst. Trade Volume: |
.07M |
Avg Inst. Trades (Per Day): |
2 |
Market Closing Trades |
Avg Closing Trade: |
$5.57M |
Avg Closing Trade (30 D): |
$3.65M |
Avg Closing Trade (90 D): |
$2.91M |
Avg Closing Volume: |
105.6K |
|
|
Financials |
|
TTM |
Q1 2025 |
Q3 2024 |
Basic EPS
|
$-1.51
|
$-.31
|
$-.28
|
Diluted EPS
|
$-1.51
|
$-.31
|
$-.28
|
Revenue
|
$ 621.71M
|
$ 154.99M
|
$ 155.1M
|
Gross Profit
|
$ 479.7M
|
$ 116.47M
|
$ 119.72M
|
Net Income / Loss
|
$ -164.19M
|
$ -34.32M
|
$ -30.57M
|
Operating Income / Loss
|
$ -166.84M
|
$ -37.87M
|
$ -32.09M
|
Cost of Revenue
|
$ 142.01M
|
$ 38.52M
|
$ 35.37M
|
Net Cash Flow
|
$ -327.93M
|
$ -36.66M
|
$ 20.76M
|
PE Ratio
|
|
|
|
|
|
|